-
A number of heads of listed pharmaceutical companies have been placed on probation, and sales expense tax violations have become an obstacle to pharmaceutical companies' ipo
1870Views
-
Pharmaceutical anti-corruption: should the use of funds through false invoicing for bribery be punished as one or several offenses?
1724Views
-
A number of well-known pharmaceutical companies were inspected! Drug company tax compliance should be the right medicine under the special rectification
The pharmaceutical industry has a bearing on people's livelihood, and is one of the areas that receive the most attention from regulators. In order to solve the problem of pharmaceutical companies in circulation to extract funds for commercial bribery, drug prices are too high, in 2017, the State Council Medical Reform Office began to implement the "two-invoice system". The "two-invoice system" has compressed the original multiple circulation links of medicines, and to a certain extent, it has cracked down on the phenomenon of price increases at various levels after the drugs leave the factory. However, the reform did not completely solve the chronic problems of the pharmaceutical industry, and the tax-related risks faced by pharmaceutical enterprises have not been eliminated. In recent years, the tax authorities at all levels announced the typical tax cases, there is no lack of pharmaceutical enterprises. This year, the General Administration of Taxation "officially announced" that pharmaceuticals are still the key area of supervision. In view of this, this article combines the current policies and regulations and typical cases to analyze and summarize the tax-related risk points in the pharmaceutical industry, so as to put forward tax compliance recommendations for pharmaceutical enterprises and help their healthy development.3298Views
-
Convicted of bribing doctors with fraudulent invoices, what can be done about tax compliance under the anti-corruption pressures?
For a long time, the pharmaceutical industry has raised the price of drugs due to potential corruption, which has given rise to a large number of false invoicing and tax evasion. For this reason, the state has repeatedly deepened the reform of the pharmaceutical system, the implementation of the "two vote system" "one vote system", in order to reduce the price of medicines, and to put an end to the bribery and corruption of medicine and other issues. Over the past few years, the state's multi-departmental joint rectification of unethical practices in the field of medicine has been normalized, and to a certain extent, it has cracked down on tax violations. But the phenomenon of bribing doctors by means of false invoicing and other means still exists. Recently, the relevant departments deployed to rectify the problem of corruption in the field of medicine, it can be seen that the pharmaceutical industry will be the state focus on regulating the industry. In view of this, this paper starts from a real case of bribing doctors through false invoicing, combines relevant policies, reveals the tax risk points of the pharmaceutical industry, and provides a tax compliance program for the pharmaceutical industry under the high pressure of anti-corruption.1006Views